Taken together, these observations indicate that, while sustained BRAF* activation in the prostate gland is sufficient to drive development of invasive prostate adenocarcinoma, it is not required for maintenance of established PCA. The gene discussed is BRAF; the disease is prostate adenocarcinoma.